myriamed™

THE DRUG DEVELOPMENT ACCELERATOR

Stroma product portfolio:

- myrCell-Stroma
- myrTissue-Stroma
- myrScreen-Stroma



PRODUCT INFORMATION

myrCell-Stroma

Human iPSC-derived fibroblasts from:



- Healthy subjects
- Patients with genetic disorders of the extracellular matrix
- CRISPR-engineered iPSC-lines
- Isogenic iPSC-lines as controls

Cryopreserved myrCells available for shipping to customer

myrTissue-Stroma

Human iPSC-derived connective tissue developed from myrCells to simulate connective tissue from:

- Healthy subjects
- Diseased subjects



Living, frozen or formaldehyde-fixed myrTissue available for shipping to customer

myrScreen-Stroma

Two-tiered phenotypic screening:



- Video-optic **myrImager** screen in 48-well **myrPlate** format
- Individual biophysical analyses of **myrTissue**

Testing of acute and chronic drug effects.
Screens designed according to customer requirements

KEY BENEFITS AT A GLANCE

- ***Human-centric drug development***
- ***Disease models and controls***
- ***Cell & tissue models on demand or custom engineered***
- ***Deep phenotyping of organotypic properties***
- ***Support by myrTeam with unsurpassed expertise***

REFERENCES

Santos et al. 2019 J Mol Cell Cardiol, Kittana et al. 2021 Int J Nanomedicine, Santos et al. 2021 J Vis Exp, Santos et al. 2022 Biomater Adv, WO2017/207431, WO2022/023451

MYRIAMED® GMBH · WWW.MYRIAMED.COM

Rudolf-Wissell-Str. 28a · 37079 Göttingen · Germany · Phone +49 551 28878-170 · Email contact@myriamed.com